GENFIT S.A. (GNFT): Price and Financial Metrics
GNFT Stock Summary
- Genfit SA's stock had its IPO on March 27, 2019, making it an older stock than merely 3.88% of US equities in our set.
- As for revenue growth, note that GNFT's revenue has grown 422.82% over the past 12 months; that beats the revenue growth of 98.19% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for GNFT comes in at -64.15% -- higher than that of merely 3.67% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Genfit SA, a group of peers worth examining would be VNE, IMOS, IPHA, MTP, and DRRX.
- Visit GNFT's SEC page to see the company's official filings. To visit the company's web site, go to www.genfit.com.
GNFT Stock Price Chart Interactive Chart >
GNFT Price/Volume Stats
| Current price | $4.87 | 52-week high | $22.48 |
| Prev. close | $5.00 | 52-week low | $3.63 |
| Day low | $4.59 | Volume | 170,916 |
| Day high | $5.00 | Avg. volume | 360,756 |
| 50-day MA | $5.27 | Dividend yield | N/A |
| 200-day MA | $5.09 | Market Cap | 189.24M |
GENFIT S.A. (GNFT) Company Bio
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
Latest GNFT News From Around the Web
Below are the latest news stories about Genfit SA that investors may wish to consider to help them evaluate GNFT as an investment opportunity.
Rhizome Partners: “INDUS (INDT) Looks, Feels, and Talks Like a Billion-Dollar Public REIT”Rhizome Partners, a long-term capital investment management firm, published its fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 18.2% was recorded by the fund for the Q4 of 2020, outperforming its S&P 500 benchmark that delivered a 12.2% return. You can view the fund’s top 5 […] |
INDUS Announces Fiscal 2020 Fourth Quarter and Full Year Earnings WebcastNEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- INDUS Realty Trust, Inc. (Nasdaq: INDT) (“INDUS” or the “Company”) announced today that it will host a pre-recorded webcast on February 19, 2021 at 8:00 A.M. Eastern Time to report on its financial results for the three months ended November 30, 2020 (“2020 fourth quarter”) and the twelve months ended November 30, 2020 (“fiscal 2020”). Supplemental materials containing additional financial and operating information will be available on INDUS’s website at the start of the webcast. All investors and other interested parties are invited to dial in to the listen-only webcast which, together with the supplemental information, can be accessed via the Investors section of INDUS’s website at www.indusrt.com/investors or the webcast can be accessed dir... |
Genfit skyrockets 150% on promising elafibranor data in chronic liver diseaseGenefit (GNFT) soars 150% after-hours on positive results from the Phase 2 trial of elafibranor in patients with Primary Biliary Cholangitis ((PBC)) with incomplete response to ursodeoxycholic acid ((UDCA)), which were published in the Journal of Hepatology.The findings were previously published on January 21, 2021 where, the dual PPARα and δ agonist elafibranor achieved the... |
Genfit Pops 29% Pre-Market On ‘Positive’ Data From Liver Disease Therapy StudyShares in Genfit popped 29% in pre-market trading on Wednesday after the late-stage biopharma company announced “positive” results from the Phase 2 clinical trial testing its elafibranor therapy in patients with Primary Biliary Cholangitis (PBC), a form of liver disease. Genfit (GNFT), which develops therapies for metabolic and liver diseases, said that the results from the Phase 2 trial of elafibranor showed a clinically relevant improvement on the primary and composite biochemical endpoints and a positive trend on pruritus improvement. At the same time, the therapy had a favorable tolerability profile. |
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of HepatologyLille, France; Cambridge, MA; February 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the positive results from the Phase 2 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC) with incomplete response to ursodeoxycholic acid (UDCA) have been published in the Journal of Hepatology. Dr. Carol Addy, CMO at GENFIT, commented: “These data support the potential for elafibranor as novel treatment in PBC and confirm the rationale of evaluating our compound in this disease in a pivotal Phase 3 trial. PBC remains a disease with significant unmet medical needs, mostly because a substantial number of patients have insufficie... |
GNFT Price Returns
| 1-mo | -5.62% |
| 3-mo | -10.81% |
| 6-mo | 3.40% |
| 1-year | -70.84% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.46% |
| 2020 | -75.88% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...